Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
The transaction is expected to close in the first quarter of 2022
The first pilot study from India analyzing Covaxin-Covishield mixed doses
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
Subscribe To Our Newsletter & Stay Updated
